What is Tafasitamab?

Tafasitamab (Tafasitamab) is a humanized CD19-directed cytolytic monoclonal antibody that contains an IgG1/2 hybrid Fc domain with 2 amino acid substitutions to modify the Fc-mediated function of the antibody. It is produced in mammalian cells (Chinese hamster ovary) through recombinant DNA technology. Tafaracetamumab, with a molecular weight of approximately 150 kDa, is an injectable preparation that is a sterile, preservative-free white to yellowish lyophilized powder in single-dose vials that can be reconstituted and further diluted for intravenous injection.

Tafaracetamumab is indicated in combination with lenalidomide for the treatment of adult patients with unspecified relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not candidates for autologous stem cell transplantation (ASCT). Tafaracetamab binds to the surface antigen CD19, causing a decrease in circulating B cell counts, which is critical for patient survival. Patients with relapsed or refractory diffuse large B-cell lymphoma experienced a 97% reduction in peripheral blood B cell counts after 8 days of treatment and a 100% reduction within 16 weeks of treatment.

Talfaracetam's single-origin generic drug has not yet been launched in the country, so it is not included in medical insurance. There are European and American versions of Tafaracetam's single-antigen drugs marketed overseas. The American version's specificationsThe price per box of 200 mg may be around 20,000 yuan, and the price of the European version's 200 mg box may be around 10,000 yuan (the price may fluctuate due to exchange rates). The ingredients of the two drugs are basically the same, but the price is more expensive. Currently, there is no generic version of Tafaracetam on the market. For more drug information and specific prices, please consult a medical consultant.